GlassScriptPhysician profile
Isaac P Thomas
NPI 1881630143
$3,088.61
in general payments reported to CMS, 2019-2025
30 companies · $553 in 2025
The $553 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $626 · 2020: $198 · 2022: $239 · 2023: $842 · 2024: $632 · 2025: $553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,027.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,026.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $420.67 | 2019-2024 | Tavneos |
| Travere Therapeutics, INC. | $363.41 | 2023-2025 | Filspari |
| Horizon Therapeutics Plc | $262.43 | 2019-2023 | Krystexxa |
| Vifor Pharma, INC. | $177.86 | 2019-2025 | Veltassa, Korsuva |
| Aurinia Pharma U.S., INC. | $165.67 | 2022-2025 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $161.06 | 2022-2024 | Terlivaz, Acthar |
| Alexion Pharmaceuticals, INC. | $149.06 | 2019-2024 | |
| Calliditas Therapeutics US INC. | $143.10 | 2023-2025 | Tarpeyo |
| Ardelyx, INC. | $135.92 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Nxstage Medical, INC. | $121.41 | 2023 | Nxstage Cartridge Express, Nxstage System One |
| Otsuka America Pharmaceutical, INC. | $121.32 | 2019-2025 | Jynarque, Voyxact |
| Bayer Healthcare Pharmaceuticals INC. | $109.92 | 2024-2025 | |
| Opko Pharmaceuticals, LLC | $100.46 | 2019-2024 | Rayaldee |
| Outset Medical INC | $93.98 | 2019 | |
| Scpharmaceuticals INC. | $91.88 | 2024-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $72.17 | 2019-2024 | Velphoro |
| Novartis Pharmaceuticals Corporation | $50.13 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $41.56 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $39.69 | 2019-2020 | |
| Boston Scientific Corporation | $35.67 | 2025 | Versacross Access Solution |
| Daiichi Sankyo INC. | $35.27 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.51 | 2024 | Jardiance |
| Akebia Therapeutics INC | $32.81 | 2019 | |
| Abbott Laboratories | $24.73 | 2025 | Cardiomems |
| Lilly USA, LLC | $24.21 | 2023 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $19.63 | 2023 | Gattex |
| Genzyme Corporation | $17.55 | 2019 | |
| Apellis Pharmaceuticals, INC. | $15.55 | 2025 | Empaveli |
| Shire North American Group INC | $13.61 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $13.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isaac Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.